$FEAM

AWM reports 3.25M shares of 5E Advanced Materials (NASDAQ: FEAM)

AWM Investment Company, Inc. has reported beneficial ownership of 3,250,000 shares of 5E Advanced Materials, Inc. (NASDAQ: FEAM), which constitutes 7.8% of the outstanding common stock. These shares are held across four distinct funds advised by AWM, with AWM exercising sole voting and dispositive power over them. The filing, a Schedule 13G, was signed on May 4, 2026, and details the holdings of each fund.

Original reporting
Published May 5, 2026, 11:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 6, 2026, 12:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$FEAM
Neutral
medium confidence
Mentioned
$FEAM
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$FEAMNeutralLow
01

Why it matters

This disclosure signals institutional interest but does not imply active management or strategic changes.

02

Market read

The filing provides insight into institutional holdings but has limited immediate trading implications.

03

What to watch

Market conditions, company fundamentals, and upcoming catalysts are not addressed; these could significantly impact stock performance.

Timing: long-term

Background

The filing is a Schedule 13G, indicating passive ownership reporting by AWM Investment Company, Inc.

Company-level read

Ticker impact

$FEAMNeutralMedium confidence
Context

The filing indicates significant institutional ownership, which can influence stock stability and investor sentiment.

Expected impact

Limited immediate price movement expected; potential for increased stability or gradual appreciation.

Evidence & confidence

The ownership stake is substantial but not controlling; market reaction depends on broader context and investor interpretation.

Market effects

The ownership disclosure does not indicate sector-specific shifts but reflects institutional interest in the materials sector.

Limited regional impact; the filing pertains to US-listed stock.

Minimal global market relevance given the specific ownership disclosure.

Counterpoint

Institutional ownership increase might precede strategic moves that could positively influence stock value.

Key entities

  • AWM Investment Company, Inc.

    A passive investment firm holding 7.8% of FEAM shares.

  • 5E Advanced Materials, Inc.

    A materials company listed on NASDAQ.

Related articles

$FEAMMed

5E Advanced Materials Secures $8 Million EXIM Investment for Fort Cady Boron Project

5E Advanced Materials (NASDAQ:FEAM) said the U.S. Export-Import Bank will invest $8 million in its Fort Cady integrated boron facility. The company said the EXIM funding precedes its application for a potential $285 million project debt facility, after receiving a letter of intent. Fort Cady is fully permitted and was highlighted by the White House under a critical minerals initiative.

$FEAMMed

5E Advanced Materials, Inc.: 5E Advanced Materials Adds to Offtake Portfolio with New Chemical Customer Agreements for Fort Cady Boric Acid

5E Advanced Materials (Nasdaq: FEAM) said it signed two multi-year offtake heads of agreement with chemical customers for technical grade granular boric acid from its Fort Cady facility. The take-or-pay deals total about 1,900 to 7,100 short tons annually, with pricing tied to the Fastmarkets index plus floor and ceiling and up to 10-year terms.

$PSXMed

Good news for San Diego drivers? A $5B fuel pipeline project advances

Phillips 66, Kinder Morgan and HF Sinclair said they made a final investment decision to proceed with the $5 billion Western Gateway Pipeline, aiming for completion in 2029 subject to permits. The 1,300-mile system would move refined fuels into the West with 230,000 bpd capacity and potential Southern California gasoline price relief. Ownership: Phillips 66 49.9%, Kinder Morgan 35.1%, HF Sinclair 15%.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.